The company has a diversified growth agenda and its execution capabilities are strong
Hero projects industry growth of 8-10% in the second half of the year. For FY26, the company has maintained its earlier guidance of 6-7% growth, indicating steady underlying demand
JLR’s operational disruptions and global macro headwinds continue to cloud earnings visibility
The company is leveraging structural industry shifts, regulatory changes, and strategic partnerships to drive growth
Most of the businesses are matured and, hence, offer predictable earnings trajectories
Despite a volatile global steel environment marked by trade barriers, demand moderation, and pricing pressure, the company performed well.
A fundamentally sound, IP-rich entertainment leader poised to capture value from India’s expanding digital and regional music markets
Strong rebound after a decline in revenues for six consecutive quarters
Sustained growth with global expansion and strong market share
The company is focusing on indigenous solutions and transitioning to a full systems integrator
Deep rural presence, robust expansion, and debt-light balance sheet to drive long-term momentum of this solar panel maker
Strong Q2, rising exports, and expanding high-margin verticals signal enduring momentum
Though the stock debuted at a 28 percent premium, there is limited upside potential in the near term
Improvement in execution and capacity expansion augur well for the company
Margin improvement, ramp-up of new glassware facility as well as the increasing share of in-house steel-ware products augur well for CWL
The financier is likely to take the lead with scalable model and balanced, risk-adjusted growth
It is a scalable play on India’s evolving healthcare demand
Short-cycle orders stay strong, QCO weighs on margins for now
The company is expanding shipbuilding capacity and exploring greenfield opportunities
Near-term earnings growth likely to be sustained, helped by strategic deals
Incremental capacity expansion at the Umbergaon facility will aid growth in the scholastic segment as manufacturing constraints ease
The company is collaborating with large pharma clients on ADC chemistry. ADCs are a class of complex molecules used in targeted cancer therapy
Strong parent backing, clean balance sheet, and huge export potential
Robust PowerGen growth, margin resilience offset temporary export softness
Risk-reward not favourable, though profitability is solid and the guidance is upbeat